LABD Valuation

Direxion Daily S&P Biotech Bear 3X Shares (LABD) is now in the Fair zone, suggesting that its current forward PS ratio of NaN is considered Fairly compared with the five-year average of --. The fair price of Direxion Daily S&P Biotech Bear 3X Shares (LABD) is between -- to -- according to relative valuation method.

LABD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Direxion Daily S&P Biotech Bear 3X Shares (LABD) is between -- to -- according to relative valuation method.

The average P/S ratio for LABD's competitors is 0.00, providing a benchmark for relative valuation. Direxion Daily S&P Biotech Bear 3X Shares Corp (LABD) exhibits a P/S ratio of --, which is 0% above the industry average. Given its robust revenue growth of 0%, this premium appears unsustainable.

As of Mar 05 2026, Direxion Daily S&P Biotech Bear 3X Shares (LABD) has a P/B ratio of NaN. This indicates that the market values LABD at NaN times its book value.

As of Mar 05 2026, Direxion Daily S&P Biotech Bear 3X Shares (LABD) has a FCF Yield of NaN%. This means that for every dollar of Direxion Daily S&P Biotech Bear 3X Shares's market capitalization, the company generates NaN cents in free cash flow.

As of Mar 05 2026, Direxion Daily S&P Biotech Bear 3X Shares (LABD) has a Forward P/E ratio of NaN. This means the market is willing to pay $NaN for every dollar of Direxion Daily S&P Biotech Bear 3X Shares's expected earnings over the next 12 months.

As of Mar 05 2026, Direxion Daily S&P Biotech Bear 3X Shares (LABD) has a Forward P/S ratio of NaN. This means the market is valuing LABD at $NaN for every dollar of expected revenue over the next 12 months.